The official blog of the Lung Institute.

This Week in Lung Disease: Quitters of Smoking Wired for Success

20 Jul 2016
| Under Lifestyle | Posted by | 4 Comments
This Week In Lung Disease

For those looking for the latest lung disease news, it can seem like an under-reported subject to those affected. That’s why we, at the Lung Institute, search the internet to find the latest news about cellular therapy, new lung disease treatments and lifestyle modifications. We do this, so you can spend less time on Google and more time doing what you love.

Study Finds Those Who Quit Smoking Are Wired for Success

Successfully quitting smoking could be all in your mind – or brain – to be more accurate. A recent study conducted at Duke University found that smokers who quit could be hard-wired in the brain for successful smoking cessation. Researchers looked at brain scans of smokers trying to quit and found that those who succeeded had greater communication between the two regions of the brain, which factor in to the urge to smoke. Those who succeeded had a stronger connection between the insula, which controls urges and cravings, and the somatosensory cortex, home to touch and motor control. More information is needed, but researchers think this is a great first step in finding new smoking cessations treatments.

You can read more about this on Fox News.

Wrinkles and Premature Aging Could Be Caused by Air Pollution

The face of someone who lives in the city may come with wrinkles and premature aging, thanks to air pollution. Emerging scientific research is finding that air pollution in urban areas can accelerate wrinkles, age spots and worsen skin conditions. Scientists in the United Kingdom state that traffic pollution is emerging as the single most toxic substance for the skin. In addition, people living in traffic-polluted areas are at greater risks of the negative effects. As more research is being conducted, skincare companies and environmental scientists will be looking for ways to help those dealing with skin damage due to air pollution and help younger generations battle this problem.

You can learn more about this on The Guardian.

Older COPD Patients at Increased Risk of Opioid-Related Complications

Those looking to for pain relief while battling chronic obstructive pulmonary disease, may need to weigh their options. A recent study finds that older adults with COPD need to be better informed about the positives and negatives of taking opioids. Opioids are medications which help to relieve pain by reducing the intensity of pain signals to the brain. Some of the risks of opioid use for older individuals with COPD include respiratory-related complications and death. It’s recommended to consult your pulmonologist about potential risks whenever starting a new a new medication or treatment plan.

You can find out more by reading the full article on Healthline.

Those with Emphysema look to ‘Renew’ Their Lungs

A CTV Toronto story highlights a new treatment option being tested to help those with emphysema. This treatment, known as Renew, involves putting tiny coils into the lungs to improve elasticity and improve the breathing of emphysema patients. For those with emphysema, the lungs harden and lose their ability to expand and contract. The Renew coils stay in permanently and won’t affect other medications. More research is being done to determine who are the best candidates for this procedure. The coils have been used in Europe since 2008, with great results.

For more information, watch the full video on CTV.

Keep checking in with us for the latest lung disease news. If you or someone you know has a chronic lung disease, remember there is hope. At the Lung Institute, we specialize in cellular therapies for those with lung diseases such as COPD, pulmonary fibrosis and interstitial lung disease. For more information about the Lung Institute or cellular therapy, please contact one of our patient coordinators by calling 888-745-6697 today.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.